Downloads
Abstract
Background: Nasopharyngeal cancer is a malignant tumor of the nasopharynx and is one of the most common cancers of the head and neck region. Chemotherapy plays a key role for the treatment of recurrent/metastatic nasopharyngeal cancer. Gemcitabine/cisplatin regimen was considered the first - line chemotherapy for the treatment of metastatic/recurrent nasopharyngeal cancer that was no longer capable of local treatment. This study aimed to assess survival outcomes and analyze the risk factors of first - line gemcitabin/cisplatin chemotherapy in metastatic/recurrent nasopharyngeal carcinoma.
Methods: Retrospective and prospective analyses of 56 patients with metastatic/recurrent nasopharyngeal carcinoma diagnosed and treated with first - line gemcitabin/cisplatin chemotherapy at National Cancer Hospital from 01/2018 to 30/10/2021.
Results: Mean progression - free survival (PFS) time was 7,81 ± 2,2 months, the at 1 - year PFS rate was estimated at 19,5%. Mean overall survival (OS) time was 30,12 ± 1,98 months, the estimated OS rates at 1 year, 2 years and 3 years were 83,2%; 70,5% and 49,3%, respectively. Mean PFS time in the group of patients with the number of distant metastases ≤ 2 organs was higher than the group with >2 distant organs. Age, sex, performance status, smoking status, pathology, and stage recurrence / metastasis were not affected survival outcome.
Conclusion: First - line gemcitabine/cisplatin chemotherapy has shown positive survival results in patients with metastatic/recurrent nasopharyngeal cancer. The number of metastatic organs has been an important factor affecting survival outcome.
References
Jin Y, Shi YX, Cai XY et al. Comparison of five cisplatin- based regimens frequently used as the first - line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012, 138(10), 1717-1725.
Zhang L, Huang Y, Hong S et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open - label, phase 3 trial. The Lancet. 2016, 388(10054), 1883-1892.
Wang J, Li J, Hong X et al. Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncol. 2007, 44(5), 464-470.
Au E, Ang PT. A phase II trial of 5 - fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 1994, 5(1), 87-89.
Wang TL, Tan Y.O. Cisplatin and 5 - fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singapore. 1991, 20(5), 601-603.
Hong S, Yaxiong Z, Gengsheng Y et al. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First - Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. Journal of Clinical Oncology. 2021; 7(1):126-130.
Yang Q, Nie YH, Cai MB et al. Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/ Metastatic Advanced Nasopharyngeal Carcinoma. Drug Design, Development and Therapy, 2022;16:162-160.
Sun XS, Wang XH et al. Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma. Front. Oncol. 2020;3(2):34-39.
Hsieh JCH, Hsu CL, Ng SH et al. Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial, Japanese Journal of Clinical Oncology. 2015; 45(9):819-827.
Toumi N, Ennouri S, Charfeddine I, Daoud J, Khanfir A. Prognostic Factors in Metastatic Nasopharyngeal Carcinoma. Braz J Otorhinolaryngol. 2022;88:212-219.
Khanfir A, Frikha M, Ghorbel A, Drira MM, Daoud J. Prognostic Factors in Metastatic Nasopharyngeal Carcinoma. Cancer Radiother. 2007;11:461-464.
| Published | 04-08-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 82 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.82.19 | |
| Keywords | Ung thư vòm, giai đoạn muộn, hoá chất gemcitabin/cisplatin, thời gian sống thêm Nasopharyngeal carcinoma, metastatic/recurrent, gemcitabin/cisplatin, survival outcome |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital